Entrada Therapeutics, Inc.
SEC CIK 1689375 · TRDA · last insider filing 2026-06-12
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| KIM Peter S | Director | filed 2021 - 2026 |
| Thistle Mary | Director | filed 2021 - 2026 |
| Parmar Kush | Director | filed 2021 - 2026 |
| Zeiher Bernhardt G | Director | filed 2023 - 2026 |
| Chapman Gina | Director | filed 2023 - 2026 |
| Radhakrishnan Maha | Director | filed 2025 - 2026 |
| Doshi Dipal | Director · President and CEO | filed 2021 - 2026 |
| Foley Todd | Director | filed 2021 - 2024 |
| Crowley John F | Director | filed 2021 - 2023 |
| Nuechterlein Carole | Director | filed 2021 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Dowden Nathan J | President & COO | filed 2021 - 2026 |
| Sethuraman Natarajan | President, Research & Develop. | filed 2021 - 2026 |
| Wentworth Kory James | Chief Financial Officer | filed 2021 - 2026 |
| Kreher Nerissa | Chief Medical Officer | filed 2021 - 2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.